Targovax (TRVX) Småprat

[Martins]

Synd at det er alltid er de små som sitter igjen med svarteper. De store kommer seg alltid inn igjen med en rettet emisjone eller lignende.

Men de store har ikke solgt. Ref top 50-listen. Dette er småaksjonærene som ødelegger for seg selv.

Det eneste jeg ser på som helt renvaskende formden emisjonen, er om de er i forhandlinger om partnerskap eller lignende, og trengte penger NÅ, for å stille sterkere i forhandlingene.

Det måtte de isåfall meldt om før emisjonen. Les reglene for emisjoner, aksjonærene skal være likestilt informasjonsmessig. Med andre ord, ingen innside-info.

[Martins]

Enig, de har litt for mye i loopen synes jeg til å være et norsk selskap. Men om de får det til på et produkt vil det finansiere de andre, så de må bare komme dit. Eventuelt kan partnere/oppkjøp ta regningen etterhvert, som vi allerede ser starten på i patentutlåningen.

[Whatsthat]

Jupp, det er det som er greia med TRVX. De skal bruke så lite som mulig på sine “små studier” som TG02, Melanoma, ONCOS X, TG01/02 + CPI for å fremskaffe gode nok data for videre samarbeid og gjerne finansiert av andre… samtidig, så må de ha en backup plan om ingen biter på, og dette er da deres “hovedfokus” Mesothelioma…

Peritoneal er untaket og jeg tror timing og innholdet av denne meldingen vil potensielt ta ONCOS til nye høyder. De samme vil gjelde for TG i inoperabel PC med parker…

[Martins]

Nå må Targo roe ned litt. Den må holde seg nede på 6kr til mandag så jeg får kjøpt med neste lønning >:(

Apropos dette, greit å få med seg at det er halvdag neste onsdag:

### Oslo Børs holder stengt følgende datoer:
2019

01.01.2019 – 1. nyttårsdag
17.04.2019 – Halv dag (onsdag før påske)
18.04.2019 – Skjærtorsdag
19.04.2019 – Langfredag
22.04.2019 – 2. påskedag
01.05.2019 – Offentlig høytidsdag
17.05.2019 – Grunnlovsdag
30.05.2019 – Kristi Himmelfartsdag
10.06.2019 – 2. pinsedag
24.12.2019 – Julaften
25.12.2019 – 1. juledag
26.12.2019 – 2. juledag
31.12.2019 – Nyttårsaften|

[TekBot]

12/04-2019 13:35:46: (TRVX) TARGOVAX ASA - APPROVAL AND PUBLICATION OF SUPPLEMENTAL PROSPECTUS

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Oslo, 12 April 2019: Reference is made to the stock exchange announcements by
Targovax ASA (OSE:TRVX) (“Targovax” or the “Company”) on 9 April 2019, regarding
(i) the publication of the annual report for the financial year 2018 and (ii)
the proposed re-scheduling of the subscription period in the subsequent offering
of up to 2,104,394 new shares in the Company, each with a par value of NOK 0.10
(the “Subsequent Offering”), as further described in the prospectus prepared by
the Company, dated 27 March 2019 (the “Prospectus”).

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today
approved the supplemental prospectus dated 12 April 2019 (the “Supplemental
Prospectus”) to the Prospectus, that has been prepared by the Company in
connection with the publication of the Company’s annual report for the financial
year 2018 and the proposed re-scheduling of the subscription period in the
Subsequent Offering. The information contained in the Supplemental Prospectus
shall be considered an integral part of, and is to be read together with, the
Prospectus.

The Prospectus and the Supplemental Prospectus are available on the following
websites: www.targovax.com and www.dnb.no/emisjoner. Hard copies of the
Prospectus and the Supplemental Prospectus may also be obtained at the offices
of Targovax ASA, Lilleakerveien 2 C, 0283 Oslo, Norway or by contacting DNB
Markets at +47 23 26 81 01.

DNB Markets will be acting as manager in the Subsequent Offering.

For further information, please contact:

Øystein Soug, CEO

Phone: +47 906 56 525

Email: oystein.soug@targovax.com

About Targovax

Activating the patient’s immune system to fight cancer Targovax (OSE:TRVX) is a
clinical stage biotechnology company developing immune activators to target hard
-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing
therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized
phaseII trial. Another trial, in checkpoint inhibitor refractory advanced
melanoma, is expected to produce important proof-of-concept immune activation
data in heavily pre-treated patients.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Directive, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Directive” means Directive 2003/71/EC as amended (together with any applicable
implementing measures in any Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.

Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.

Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement.

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is subject to disclosure requirements pursuant to Section 5-12
of the Norwegian Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190412.OBI.20190412S66

[Whatsthat]

Ref disse vinduene som de nevnte sist podcast og din liste. Er det slik at TRVX ikke kan offentliggjøre/ børsmelde ting 14 dager før kvartalspresentasjon 9 mai?

17.04.2019 – Halv dag (onsdag før påske)
18.04.2019 – Skjærtorsdag
19.04.2019 – Langfredag
22.04.2019 – 2. påskedag

25.04-09.05 - 14 dager før kvartalspresentaajon.

De vil gi 4-5 handelsdager og frist frem til 25.04 til å børsmelde…

Stemmer dette?

[Boms]

Vesentlig informasjon skal meldes så fort som mulig. I spesielle tilfeller kan de orientere børsen om at noe “er på gang” og børsen vil da forsøke å se etter tegn på lekkasjer av innsideinformasjon.

[Whatsthat]

Hmm… tenker mer på det scenarioet her; 29 april - trvx for cohort 1 data fra melanom. Må de da vente til etter kvartalspresentasjon 9 mai for å børsmelde?

[Boms]

Nei! Hvorfor skulle de det.
Reglene er ganske klare: Utsteder skal uoppfordret og umiddelbart offentliggjøre innsideinformasjon som direkte angår utsteder, jf. § 3-2 første til tredje ledd.
Kommer det store gode eller dårlige nyheter vil jo investorene handle i blinde i en lang periode, se linken under.

Lov om verdipapirhandel (verdipapirhandelloven) - I. Løpende informasjonsplikt...

[Oilimp]

Er det slik at TRVX ikke kan offentliggjøre/ børsmelde ting 14 dager før kvartalspresentasjon 9 mai?

Såkalte stilleperioder før q-presentasjoner betyr at de ikke svarer på henvendelser o.l, men de børsmelder som vanlig ved nyheter.
Det er sånn hos Nano, så reglene er nok like her.

[Whatsthat]

Det gir mening. Håpet denne “stilleperioden” gjaldt flere ting.

Tenker å posisjonere meg ytterligere inn før 3 års data, da er det greit å vite hva som gjelder…

[Whatsthat]

Å… forresten, usikker på om folk fikk det med seg dette sist…

Pasientene i Cohort 2 er tett rekrutert… og 2 års leses da siste pasient hadde overlevd mer enn 24 mnd…

Slik jeg tolker grafen fra sist 2 års utlesning var det 9 pasienter som fremdeles levde i intervallet 26mnd - 34mnd, så nå i mai får vi egentlig 38-46mnd data…

[Rodjer]

Jeg kan hvertfall garantere en ting og det er at jeg ikke er noen sin mor.

[Markusf]

Etter å ha vært inne i flere runder - var bl.a med i emisjonen på 20 “sist” gang - tror jeg bunnen er nådd, og om jeg skal finne noe positivt, har jeg aldri eid så mange aksjer i trvx som nå - så får heller trøste meg med store fratrekk på skatten for 2018 som en konsekvens av mitt tidligere eierskap i trvx :-/
Fremtiden er lys & og ble overbevist etter å ha hørt igjennom forrige radforsk en gang til

[Guny]

Kjenner meg igjen i det du skriver her! Har vært inne siden slutten av 2016, begynte smått. Kjøpt på de fleste nivåer! Solgt litt, fradrag på skatt! Var så å si break even før emi😰 Men har kjøpt litt til, og har et bra antall aksjer! Trodde aldri jeg skulle sitte på det antallet jeg har nå! Ikke Aborum nivå, men nok til å kunne ha det økonomisk romslig, hvis dette går veien👍Har alltid hatt trua, ikke noen dårlige avlesninger til nå👍

[BioMed]

Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.

APRIL 11, 2019

[busk1]

Fikk ikke lenken din til å virke @BioMed
Ser ut som det er samme tittel som artikkelen som ble publisert her i OnkoImmunology i oktober i fjor

[BioMed]

MesotheliomaHelpNow (MesoHelpNow)

[blaahval]

Ny liste:
Ikke begynne å kaldsvett over “nedsalget” på toppen. Disse aksjene vil være på plass om 2 uker igjen

Ellers kan man jo lure på hva emi-kameratene tenker når de selger videre med tap.

[Buffet]

Investoren bak Merrill lynch helt ute ja. Ja det var viktig og tilrettelegge en emisjon for disse langsiktige, viktige utelandske investorene som Soug kalte de…